Total homocysteine lowering treatment among coronary artery disease patients in the era of folic acid-fortified cereal grain flour
- PMID: 11884295
- DOI: 10.1161/hq0302.105369
Total homocysteine lowering treatment among coronary artery disease patients in the era of folic acid-fortified cereal grain flour
Abstract
The prevalence of deficient plasma folate status and elevated total plasma levels of homocysteine (tHcy), have been dramatically reduced after fortification of all enriched cereal grain flour products with folic acid at 140 microg/100 g flour. Against this new background fortification, we evaluated the tHcy-lowering efficacy of pharmacological dose, folic acid-based vitamin B supplementation among stable coronary artery disease (CAD) patients. Using a 2x2 factorial design, 131 stable CAD patients (mean age 60.1 years; 29.8% women) were randomly assigned to receive a combination of folic acid 2.5 mg/d, riboflavin 5 mg/d, + B12 0.4 mg/d, or placebo, with or without vitamin B6 50 mg/d, for 12 weeks of treatment. ANCOVA adjusted for baseline fasting tHcy levels revealed only very modest (ie, approximately 1.0 micromol/L), albeit statistically significant (P<0.05), reductions in mean fasting tHcy levels afforded by the folic acid-containing treatments. Additional analyses indicated that none of the treatments provided a statistically significant reduction in the 2-hour post-methionine increase in tHcy levels, relative to placebo treatment. CAD patients exposed to cereal grain flour products fortified with folic acid who receive high-dose, folic acid-containing vitamin B regimens, experience only very modest reductions in their mean fasting plasma tHcy levels. These findings have important implications for the statistical power of clinical trials testing the hypothesis that tHcy-lowering treatment may reduce recurrent atherothrombotic event rates.
Comment in
-
Validation of homocyst(e)ine-lowering treatment in the era of folic acid fortification of cereal grains.Arterioscler Thromb Vasc Biol. 2002 Jun 1;22(6):1051; author reply 1051. Arterioscler Thromb Vasc Biol. 2002. PMID: 12067920 No abstract available.
Similar articles
-
Renal insufficiency, vitamin B(12) status, and population attributable risk for mild hyperhomocysteinemia among coronary artery disease patients in the era of folic acid-fortified cereal grain flour.Arterioscler Thromb Vasc Biol. 2001 May;21(5):849-51. doi: 10.1161/01.atv.21.5.849. Arterioscler Thromb Vasc Biol. 2001. PMID: 11348885
-
Prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease patients after fortification of cereal grain flour with folic acid.Atherosclerosis. 1999 Jul;145(1):221-4. doi: 10.1016/s0021-9150(99)00023-4. Atherosclerosis. 1999. PMID: 10428313
-
Power Shortage: clinical trials testing the "homocysteine hypothesis" against a background of folic acid-fortified cereal grain flour.Ann Intern Med. 2001 Jul 17;135(2):133-7. doi: 10.7326/0003-4819-135-2-200107170-00014. Ann Intern Med. 2001. PMID: 11453713
-
Homocysteine, B-vitamins and CVD.Proc Nutr Soc. 2008 May;67(2):232-7. doi: 10.1017/S0029665108007076. Proc Nutr Soc. 2008. PMID: 18412997 Review.
-
DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations.Clin Chem Lab Med. 2003 Nov;41(11):1392-403. doi: 10.1515/CCLM.2003.214. Clin Chem Lab Med. 2003. PMID: 14656016 Review.
Cited by
-
Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohorts.Arch Intern Med. 2009 Feb 9;169(3):294-304. doi: 10.1001/archinternmed.2008.540. Arch Intern Med. 2009. PMID: 19204221 Free PMC article.
-
Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial.JAMA. 2008 May 7;299(17):2027-36. doi: 10.1001/jama.299.17.2027. JAMA. 2008. PMID: 18460663 Free PMC article. Clinical Trial.
-
Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial.Can J Cardiol. 2006 Jan;22(1):47-53. doi: 10.1016/s0828-282x(06)70238-0. Can J Cardiol. 2006. PMID: 16450017 Free PMC article. Clinical Trial.
-
Quo vadis: whither homocysteine research?Cardiovasc Toxicol. 2009 Jun;9(2):53-63. doi: 10.1007/s12012-009-9042-6. Epub 2009 May 30. Cardiovasc Toxicol. 2009. PMID: 19484390 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous